BeOne Medicines’ Beqalzi (sonrotoclax) Gets FDA Approval as First BCL2 Inhibitor for Relapsed or Refractory Mantle Cell Lymphoma | iPharmaCenter
- Badari Andukuri
- May 16
- 2 min read
BeOne Medicines announced that the U.S. FDA has granted accelerated approval to Beqalzi (sonrotoclax), the first and only BCL2 inhibitor approved for relapsed or refractory (R/R) mantle cell lymphoma (MCL) in the United States.
Beqalzi is approved for adult patients who have received at least two prior systemic therapies, including a Bruton’s tyrosine kinase (BTK) inhibitor. This marks the first new BCL2 inhibitor approved in the U.S. in a decade and establishes a new standard of innovation for MCL treatment.
What is mechanism of action of Beqalzi?
Beqalzi is a next-generation, foundational BCL2 inhibitor designed with greater potency and selectivity than other drugs in the class, with the potential to deliver better efficacy, improved tolerability, and greater convenience for patients.
What Key Clinical Trial Outcomes Supported Beqalzi Approval?
The FDA’s accelerated approval of Beqalzi is based on efficacy and safety results from the Phase 1/2 BGB-11417-201 clinical trial (NCT05471843), a single-arm, multicenter study that enrolled adults with R/R MCL who had received prior anti-CD20 therapy and a BTK inhibitor.
An independent review committee assessed responses using the 2014 Lugano criteria, and the key outcomes that supported approval were:
Overall response rate (ORR): 52%, the primary endpoint of the study
Complete response (CR) rate: 16%
Median time to response (TTR): 1.9 months, indicating relatively rapid onset of action
Median duration of response (DOR): 15.8 months at a median follow-up of 11.9 months, showing durable responses
Safety profile: Sonrotoclax monotherapy was generally well tolerated, with treatment-emergent adverse events mostly blood-related, manageable, and leading to discontinuation in 13.9% of patients
These results met the study’s primary endpoint and demonstrated clinically meaningful and durable responses in a heavily pretreated patient population with limited treatment options. Continued approval is contingent on confirmation of clinical benefit in the ongoing confirmatory Phase 3 CELESTIAL-RRMCL trial (NCT06742996). The FDA also granted Breakthrough Therapy Designation, Fast Track Designation, and Orphan Drug Designation for sonrotoclax in R/R MCL.
Also read: UnitedHealthcare Reduces Prior Authorization Requirements by 30% and Standardizes Electronic Submissions
Why Beqalzi Matters for Mantle Cell Lymphoma Patients?
Mantle cell lymphoma is a rare and aggressive subtype of non-Hodgkin lymphoma, with about 3,300 new cases diagnosed each year in the United States. Relapse is common after initial therapy, and outcomes after progression, particularly following BTK inhibitor treatment, are often poor. Beqalzi introduces a new targeted mechanism for this challenging post, BTK inhibitor setting, expanding treatment options as the disease evolves.
Beqalzi is also approved in China for R/R MCL and for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in patients who have received at least one prior systemic therapy including a BTK inhibitor. Regulatory reviews for Beqalzi in R/R MCL are ongoing with the European Medicines Agency and other agencies worldwide.
Comments